• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail


Audience: Healthcare professionals, Consumers

The FDA is warning consumers to immediately stop use of the product Lipokinetix, marketed as a dietary supplement (for weight loss) by Syntrax Innovations, Inc. FDA has received multiple reports of persons who developed liver injury or liver failure while using Lipokinetix. The product contains norephedrine (also known as phenylpropanolamine or PPA), caffeine, yohimbine, diiodothyronine, and sodium usniate. FDA is also advising consumers to consult their physician if they are experiencing symptoms possibly associated with this product, particularly nausea, weakness or fatigue, fever, abdominal pain, or any change in skin color.

[Nov 20, 2001 - Letter - FDA] PDF Format